AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?

The article favors AbbVie for 2027, citing FY 2025 revenue growth of 8.6% to about $61.2 billion and expectations for sales of $67.2 billion and net income of $14.6 billion this year, up from $4.2 billion. Skyrizi and Rinvoq are driving growth, though patent expirations, customer concentration and pricing pressure remain risks. Bristol Myers Squibb reported FY 2025 revenue down 0.2% to $48.2 billion and a return to $7.1 billion in net income; its lower forward P/E of 9.7x versus AbbVie’s 21.2x reflects a less certain turnaround.

Analysis

The key underwriting issue is whether AbbVie’s growth is durable enough to earn its valuation premium—not simply whether legacy-drug declines are being offset today. Skyrizi/Rinvoq make the transition credible, but their combined concentration creates a new single-franchise risk: any safety, access, or competitive setback could hit both growth and the multiple at once. Verify prescription trends, payer access, and product-level guidance rather than extrapolating company-wide revenue growth. The distributor concentration is less clearly an equity catalyst: higher drug volumes may lift throughput at McKesson, Cardinal Health, and Cencora, but does not establish improved distributor economics or bargaining power.

Bristol Myers Squibb’s low multiple may already discount patent erosion, yet a reported earnings rebound is not enough to establish a durable turnaround. Reconcile GAAP and adjusted earnings, litigation charges, and product-level launch contributions before treating the rebound as recurring. IRA negotiation exposure and exclusivity losses are multi-quarter risks; the Celgene litigation is a discrete downside catalyst. AbbVie’s Parkinson’s opportunity is further out, with reimbursement timing limiting near-term value.

Contrarian view: AbbVie’s premium could be vulnerable if investors are already paying for sustained immunology growth and pipeline optionality. Conversely, BMY’s discount can support a sharp rerating if launches replace erosion faster than expected. There is no clean directional trade from this article alone; the relative opportunity is conditional on upcoming product-level results.

Key Decisions for Investors

• Prefer a staged, relative-value position over an outright BMY short: consider a modest long ABBV / short BMY pair only after verifying comparable adjusted EPS and confirming continued Skyrizi/Rinvoq momentum. Keep exposure limited; BMY’s low valuation creates squeeze risk if launch data or guidance surprises positively.
• For the next 1–3 months, monitor ABBV product-level growth and access commentary, and BMY launch contribution, exclusivity erosion, and litigation updates. Do not underwrite the cited AbbVie net-income step-up until GAAP-to-adjusted earnings and acquisition-related effects are reconciled.
• Falsify the ABBV-over-BMY thesis if AbbVie cuts immunology growth expectations or reports material access/safety deterioration, while BMY raises recurring earnings guidance on launches that offset legacy erosion. Reassess the pair if those conditions narrow the expected growth gap.
• No direct trade in MCK, CAH, or COR on this evidence: wholesaler exposure indicates distribution dependence, not a demonstrated change in their margins or earnings outlook.